ATLANTA, Feb. 12, 2020 /PRNewswire/ — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, today announced it has initiated its first-in-human Phase I clinical trial for ATI-2173, a novel liver-targeted, orally-administered, small molecule against hepatitis B. The Phase Ia study is a randomized, double-blind, placebo-controlled single-ascending dose (“SAD”) study in healthy volunteers to evaluate the compound’s safety, tolerability and pharmacokinetic profile.
This SAD study will be conducted in up to 35 healthy subjects randomized into 5 cohorts of 7 subjects each. A Phase Ib multiple-ascending dose (“MAD”) clinical study in HBV-infected subjects is planned to commence following the completion of the SAD and MAD cohorts for the Phase Ia study.
“Dosing the first patients with ATI-2173 is a significant milestone for our company and we are very excited to initiate the first-in-human study of our liver-targeted, non-chain terminating, HBV polymerase inhibitor,” said Abel De La Rosa, Ph.D., CEO of Antios.
“We are looking forward to learning more about ATI-2173 in the clinic after obtaining very encouraging preclinical antiviral activity and preclinical safety data for our lead molecule,” said Douglas Mayers M.D., CMO of Antios.
Additional information can be found on www.clinicaltrials.gov
ATI-2173 is a novel liver-targeted molecule designed to deliver the 5′-monophosphate of clevudine. This L-nucleoside’s active 5′-triphosphate has unique antiviral properties as a non-competitive, non-chain terminating HBV polymerase inhibitor. By selectively delivering the 5′-monophosphate to the liver, while retaining the unique anti-HBV activity of the active 5′- triphosphate, ATI-2173 could become an integral part of a curative combination regimen for chronic hepatitis B.
About Antios Therapeutics Inc.
Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases. Antios is currently developing ATI-2173, aiming to provide chronic hepatitis B infected patients with a curative combination regimen.
SOURCE Antios Therapeutics, Inc.